Non-alcoholic Steatohepatitis Drug Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $3,500	104 Pages	Prof-Research	April, 2025	PROF19900407

Best Price Guarantee
Price	from $3,500
Length	104 Pages
Publisher	Prof-Research
Published Date	April, 2025
SKU	PROF19900407

Non-alcoholic Steatohepatitis Drug Market Summary
Introduction
Non-alcoholic Steatohepatitis (NASH) is a severe form of non-alcoholic fatty liver disease marked by liver inflammation and fibrosis, often linked to obesity and metabolic syndrome. Globally, NASH prevalence rose from 264 million in 2018 to 296 million in 2023, projected to reach 342 million by 2030. The NASH Drug market focuses on therapies to halt progression, reduce fat accumulation, and prevent cirrhosis, with resmetirom—approved by the FDA in March 2024 by Madrigal Pharmaceuticals—as the first drug for moderate-to-advanced NASH fibrosis. The industry is characterized by intense R&D, addressing a growing epidemic with significant unmet needs and a shift toward metabolic-targeted therapies.

Market Size and Growth Forecast
The global Non-alcoholic Steatohepatitis Drug market is estimated at USD 0.3 billion to USD 0.6 billion in 2025, with an extraordinary CAGR of 100% to 110% through 2030, potentially reaching USD 10 billion to USD 24 billion. This explosive growth reflects resmetirom’s approval and robust pipeline activity.

Regional Analysis
North America: Expected at 95% to 105%, the U.S. leads with high obesity rates and advanced healthcare. Trends focus on metabolic drugs and diagnostics.
Europe: Forecasted at 90% to 100%, Germany and France grow rapidly. Trends emphasize lifestyle-linked therapies.
Asia Pacific: Projected at 100% to 110%, China drives growth with rising prevalence. Trends highlight local R&D.
South Ameica: Anticipated at 85% to 95%, Brazil emerges. Trends favor affordable options.
Middle East and Africa: Expected at 80% to 90%, UAE leads. Trends focus on awareness and access.

Key Market Players
AstraZeneca PLC: A UK leader, AstraZeneca targets metabolic diseases like NASH.
Eli Lilly: A U.S. firm, Lilly advances NASH therapies with metabolic focus.
Gilead Sciences: A U.S. giant, Gilead explores liver disease solutions.
Merck & Co. Inc.: A U.S. player, Merck innovates in NASH treatments.
Novo Nordisk: A Danish company, Novo Nordisk leverages diabetes expertise for NASH.
Novartis AG: A Swiss firm, Novartis focuses on fibrosis therapies.
Pfizer Inc.: A U.S. leader, Pfizer targets metabolic liver conditions.
Roche Holding AG: A Swiss giant, Roche explores NASH innovations.
Enanta Pharmaceuticals Inc.: A U.S. biotech, Enanta develops liver-targeted drugs.
Ionis Pharmaceuticals Inc.: A U.S. entity, Ionis advances RNA therapies for NASH.
NGM Biopharmaceuticals Inc.: A U.S. firm, NGM targets metabolic pathways.
Pliant Therapeutics Inc.: A U.S. biotech, Pliant focuses on anti-fibrotic agents.
Terns Pharmaceuticals Inc.: A U.S. company, Terns innovates in NASH treatments.
89bio Inc.: A U.S. entity, 89bio develops metabolic therapies.

Porter’s Five Forces Analysis
Threat of New Entrants: High, with blockbuster potential attracting biotechs despite R&D costs.
Threat of Substitutes: Moderate, with lifestyle interventions competing, but drugs offer scalability.
Bargaining Power of Buyers: Moderate, as unmet needs limit options, though insurers push pricing.
Bargaining Power of Suppliers: Low-to-moderate, with broad supply chains supporting drug production.
Competitive Rivalry: Intense, driven by first-mover advantages and pipeline races among Gilead and Merck.

Market Opportunities and Challenges
Opportunities
Rising Prevalence: 342 million cases by 2030 create vast demand for NASH drugs.
First Approval: Resmetirom’s success sets a precedent, accelerating market entry.
Metabolic Focus: Overlap with obesity and diabetes opens cross-therapeutic potential.
Investment Surge: High growth rates attract significant R&D funding.
Challenges
Diagnostic Barriers: NASH’s silent progression delays treatment, limiting market reach.
High Costs: Expensive drugs like resmetirom challenge affordability in emerging markets.
Regulatory Hurdles: Rigorous efficacy proof slows pipeline approvals.
Competition: Crowded pipeline increases rivalry, risking market saturation.

Chapter 1 Executive Summary
Chapter 2 Abbreviation and Acronyms
Chapter 3 Preface: 3.1 Research Scope; 3.2 Research Sources; 3.2.1 Data Sources; 3.2.2 Assumptions; 3.3 Research Method
Chapter Four Market Landscape: 4.1 Market Overview; 4.2 Classification/Types; 4.3 Application/End Users
Chapter 5 Market Trend Analysis: 5.1 Introduction; 5.2 Drivers; 5.3 Restraints; 5.4 Opportunities; 5.5 Threats
Chapter 6 Industry Chain Analysis: 6.1 Upstream/Suppliers Analysis; 6.2 Non-Alcoholic Steatohepatitis Drug Analysis; 6.2.1 Technology Analysis; 6.2.2 Cost Analysis; 6.2.3 Market Channel Analysis; 6.3 Downstream Buyers/End Users
Chapter 7 Latest Market Dynamics: 7.1 Latest News; 7.2 Merger and Acquisition; 7.3 Planned/Future Project; 7.4 Policy Dynamics
Chapter 8 Historical and Forecast Non-Alcoholic Steatohepatitis Drug Market in North America (2020-2030): 8.1 Non-Alcoholic Steatohepatitis Drug Market Size; 8.2 Non-Alcoholic Steatohepatitis Drug Market by End Use; 8.3 Competition by Players/Suppliers; 8.4 Non-Alcoholic Steatohepatitis Drug Market Size by Type; 8.5 Key Countries Analysis; 8.5.1 United States; 8.5.2 Canada; 8.5.3 Mexico
Chapter 9 Historical and Forecast Non-Alcoholic Steatohepatitis Drug Market in South America (2020-2030): 9.1 Non-Alcoholic Steatohepatitis Drug Market Size; 9.2 Non-Alcoholic Steatohepatitis Drug Market by End Use; 9.3 Competition by Players/Suppliers; 9.4 Non-Alcoholic Steatohepatitis Drug Market Size by Type; 9.5 Key Countries Analysis; 9.5.1 Brazil; 9.5.2 Argentina; 9.5.3 Chile; 9.5.4 Peru
Chapter 10 Historical and Forecast Non-Alcoholic Steatohepatitis Drug Market in Asia & Pacific (2020-2030): 10.1 Non-Alcoholic Steatohepatitis Drug Market Size; 10.2 Non-Alcoholic Steatohepatitis Drug Market by End Use; 10.3 Competition by Players/Suppliers; 10.4 Non-Alcoholic Steatohepatitis Drug Market Size by Type; 10.5 Key Countries Analysis; 10.5.1 China; 10.5.2 India; 10.5.3 Japan; 10.5.4 South Korea; 10.5.5 Southest Asia; 10.5.6 Australia
Chapter 11 Historical and Forecast Non-Alcoholic Steatohepatitis Drug Market in Europe (2020-2030): 11.1 Non-Alcoholic Steatohepatitis Drug Market Size; 11.2 Non-Alcoholic Steatohepatitis Drug Market by End Use; 11.3 Competition by Players/Suppliers; 11.4 Non-Alcoholic Steatohepatitis Drug Market Size by Type; 11.5 Key Countries Analysis; 11.5.1 Germany; 11.5.2 France; 11.5.3 United Kingdom; 11.5.4 Italy; 11.5.5 Spain; 11.5.6 Belgium; 11.5.7 Netherlands; 11.5.8 Austria; 11.5.9 Poland; 11.5.10 Russia
Chapter 12 Historical and Forecast Non-Alcoholic Steatohepatitis Drug Market in MEA (2020-2030): 12.1 Non-Alcoholic Steatohepatitis Drug Market Size; 12.2 Non-Alcoholic Steatohepatitis Drug Market by End Use; 12.3 Competition by Players/Suppliers; 12.4 Non-Alcoholic Steatohepatitis Drug Market Size by Type; 12.5 Key Countries Analysis; 12.5.1 Egypt; 12.5.2 Israel; 12.5.3 South Africa; 12.5.4 Gulf Cooperation Council Countries; 12.5.5 Turkey
Chapter 13 Summary For Global Non-Alcoholic Steatohepatitis Drug Market (2020-2025): 13.1 Non-Alcoholic Steatohepatitis Drug Market Size; 13.2 Non-Alcoholic Steatohepatitis Drug Market by End Use; 13.3 Competition by Players/Suppliers; 13.4 Non-Alcoholic Steatohepatitis Drug Market Size by Type
Chapter 14 Global Non-Alcoholic Steatohepatitis Drug Market Forecast (2025-2030): 14.1 Non-Alcoholic Steatohepatitis Drug Market Size Forecast; 14.2 Non-Alcoholic Steatohepatitis Drug Application Forecast; 14.3 Competition by Players/Suppliers; 14.4 Non-Alcoholic Steatohepatitis Drug Type Forecast
Chapter 15 Analysis of Global Key Vendors: 15.1 AstraZeneca PLC; 15.1.1 Company Profile; 15.1.2 Main Business and Non-alcoholic Steatohepatitis Drug Information; 15.1.3 SWOT Analysis of AstraZeneca PLC; 15.1.4 AstraZeneca PLC Non-alcoholic Steatohepatitis Drug Revenue, Gross Margin and Market Share (2020-2025); 15.2 Eli Lilly; 15.2.1 Company Profile; 15.2.2 Main Business and Non-alcoholic Steatohepatitis Drug Information; 15.2.3 SWOT Analysis of Eli Lilly; 15.2.4 Eli Lilly Non-alcoholic Steatohepatitis Drug Revenue, Gross Margin and Market Share (2020-2025); 15.3 Gilead Sciences; 15.3.1 Company Profile; 15.3.2 Main Business and Non-alcoholic Steatohepatitis Drug Information; 15.3.3 SWOT Analysis of Gilead Sciences; 15.3.4 Gilead Sciences Non-alcoholic Steatohepatitis Drug Revenue, Gross Margin and Market Share (2020-2025); 15.4 Merck & Co. Inc.; 15.4.1 Company Profile; 15.4.2 Main Business and Non-alcoholic Steatohepatitis Drug Information; 15.4.3 SWOT Analysis of Merck & Co. Inc.; 15.4.4 Merck & Co. Inc. Non-alcoholic Steatohepatitis Drug Revenue, Gross Margin and Market Share (2020-2025); 15.5 Novo Nordisk; 15.5.1 Company Profile; 15.5.2 Main Business and Non-alcoholic Steatohepatitis Drug Information; 15.5.3 SWOT Analysis of Novo Nordisk; 15.5.4 Novo Nordisk Non-alcoholic Steatohepatitis Drug Revenue, Gross Margin and Market Share (2020-2025); 15.6 Novartis AG; 15.6.1 Company Profile; 15.6.2 Main Business and Non-alcoholic Steatohepatitis Drug Information; 15.6.3 SWOT Analysis of Novartis AG; 15.6.4 Novartis AG Non-alcoholic Steatohepatitis Drug Revenue, Gross Margin and Market Share (2020-2025); 15.7 Pfizer Inc.; 15.7.1 Company Profile; 15.7.2 Main Business and Non-alcoholic Steatohepatitis Drug Information; 15.7.3 SWOT Analysis of Pfizer Inc.; 15.7.4 Pfizer Inc. Non-alcoholic Steatohepatitis Drug Revenue, Gross Margin and Market Share (2020-2025); 15.8 Roche Holding AG; 15.8.1 Company Profile; 15.8.2 Main Business and Non-alcoholic Steatohepatitis Drug Information; 15.8.3 SWOT Analysis of Roche Holding AG; 15.8.4 Roche Holding AG Non-alcoholic Steatohepatitis Drug Revenue, Gross Margin and Market Share (2020-2025); 15.9 Enanta Pharmaceuticals Inc.; 15.9.1 Company Profile; 15.9.2 Main Business and Non-alcoholic Steatohepatitis Drug Information; 15.9.3 SWOT Analysis of Enanta Pharmaceuticals Inc.; 15.9.4 Enanta Pharmaceuticals Inc. Non-alcoholic Steatohepatitis Drug Revenue, Gross Margin and Market Share (2020-2025); 15.10 Ionis Pharmceuticals Inc.; 15.10.1 Company Profile; 15.10.2 Main Business and Non-alcoholic Steatohepatitis Drug Information; 15.10.3 SWOT Analysis of Ionis Pharmceuticals Inc.; 15.10.4 Ionis Pharmceuticals Inc. Non-alcoholic Steatohepatitis Drug Revenue, Gross Margin and Market Share (2020-2025); Please ask for sample pages for full companies list
Tables and Figures: Table Abbreviation and Acronyms; Table Research Scope of Non-Alcoholic Steatohepatitis Drug Report; Table Data Sources of Non-Alcoholic Steatohepatitis Drug Report; Table Major Assumptions of Non-Alcoholic Steatohepatitis Drug Report; Figure Market Size Estimated Method; Figure Major Forecasting Factors; Figure Non-Alcoholic Steatohepatitis Drug Picture; Table Non-Alcoholic Steatohepatitis Drug Classification; Table Non-Alcoholic Steatohepatitis Drug Applications; Table Drivers of Non-Alcoholic Steatohepatitis Drug Market; Table Restraints of Non-Alcoholic Steatohepatitis Drug Market; Table Opportunities of Non-Alcoholic Steatohepatitis Drug Market; Table Threats of Non-Alcoholic Steatohepatitis Drug Market; Table Covid-19 Impact For Non-Alcoholic Steatohepatitis Drug Market; Table Raw Materials Suppliers; Table Different Production Methods of Non-Alcoholic Steatohepatitis Drug; Table Cost Structure Analysis of Non-Alcoholic Steatohepatitis Drug; Table Key End Users; Table Latest News of Non-Alcoholic Steatohepatitis Drug Market; Table Merger and Acquisition; Table Planned/Future Project of Non-Alcoholic Steatohepatitis Drug Market; Table Policy of Non-Alcoholic Steatohepatitis Drug Market; Table 2020-2030 North America Non-Alcoholic Steatohepatitis Drug Market Size; Figure 2020-2030 North America Non-Alcoholic Steatohepatitis Drug Market Size and CAGR; Table 2020-2030 North America Non-Alcoholic Steatohepatitis Drug Market Size by Application; Table 2020-2025 North America Non-Alcoholic Steatohepatitis Drug Key Players Revenue; Table 2020-2025 North America Non-Alcoholic Steatohepatitis Drug Key Players Market Share; Table 2020-2030 North America Non-Alcoholic Steatohepatitis Drug Market Size by Type; Table 2020-2030 United States Non-Alcoholic Steatohepatitis Drug Market Size; Table 2020-2030 Canada Non-Alcoholic Steatohepatitis Drug Market Size; Table 2020-2030 Mexico Non-Alcoholic Steatohepatitis Drug Market Size; Table 2020-2030 South America Non-Alcoholic Steatohepatitis Drug Market Size; Figure 2020-2030 South America Non-Alcoholic Steatohepatitis Drug Market Size and CAGR; Table 2020-2030 South America Non-Alcoholic Steatohepatitis Drug Market Size by Application; Table 2020-2025 South America Non-Alcoholic Steatohepatitis Drug Key Players Revenue; Table 2020-2025 South America Non-Alcoholic Steatohepatitis Drug Key Players Market Share; Table 2020-2030 South America Non-Alcoholic Steatohepatitis Drug Market Size by Type; Table 2020-2030 Brazil Non-Alcoholic Steatohepatitis Drug Market Size; Table 2020-2030 Argentina Non-Alcoholic Steatohepatitis Drug Market Size; Table 2020-2030 Chile Non-Alcoholic Steatohepatitis Drug Market Size; Table 2020-2030 Peru Non-Alcoholic Steatohepatitis Drug Market Size; Table 2020-2030 Asia & Pacific Non-Alcoholic Steatohepatitis Drug Market Size; Figure 2020-2030 Asia & Pacific Non-Alcoholic Steatohepatitis Drug Market Size and CAGR; Table 2020-2030 Asia & Pacific Non-Alcoholic Steatohepatitis Drug Market Size by Application; Table 2020-2025 Asia & Pacific Non-Alcoholic Steatohepatitis Drug Key Players Revenue; Table 2020-2025 Asia & Pacific Non-Alcoholic Steatohepatitis Drug Key Players Market Share; Table 2020-2030 Asia & Pacific Non-Alcoholic Steatohepatitis Drug Market Size by Type; Table 2020-2030 China Non-Alcoholic Steatohepatitis Drug Market Size; Table 2020-2030 India Non-Alcoholic Steatohepatitis Drug Market Size; Table 2020-2030 Japan Non-Alcoholic Steatohepatitis Drug Market Size; Table 2020-2030 South Korea Non-Alcoholic Steatohepatitis Drug Market Size; Table 2020-2030 Southeast Asia Non-Alcoholic Steatohepatitis Drug Market Size; Table 2020-2030 Australia Non-Alcoholic Steatohepatitis Drug Market Size; Table 2020-2030 Europe Non-Alcoholic Steatohepatitis Drug Market Size; Figure 2020-2030 Europe Non-Alcoholic Steatohepatitis Drug Market Size and CAGR; Table 2020-2030 Europe Non-Alcoholic Steatohepatitis Drug Market Size by Application; Table 2020-2025 Europe Non-Alcoholic Steatohepatitis Drug Key Players Revenue; Table 2020-2025 Europe Non-Alcoholic Steatohepatitis Drug Key Players Market Share; Table 2020-2030 Europe Non-Alcoholic Steatohepatitis Drug Market Size by Type; Table 2020-2030 Germany Non-Alcoholic Steatohepatitis Drug Market Size; Table 2020-2030 France Non-Alcoholic Steatohepatitis Drug Market Size; Table 2020-2030 United Kingdom Non-Alcoholic Steatohepatitis Drug Market Size; Table 2020-2030 Italy Non-Alcoholic Steatohepatitis Drug Market Size; Table 2020-2030 Spain Non-Alcoholic Steatohepatitis Drug Market Size; Table 2020-2030 Belgium Non-Alcoholic Steatohepatitis Drug Market Size; Table 2020-2030 Netherlands Non-Alcoholic Steatohepatitis Drug Market Size; Table 2020-2030 Austria Non-Alcoholic Steatohepatitis Drug Market Size; Table 2020-2030 Poland Non-Alcoholic Steatohepatitis Drug Market Size; Table 2020-2030 Russia Non-Alcoholic Steatohepatitis Drug Market Size; Table 2020-2030 MEA Non-Alcoholic Steatohepatitis Drug Market Size; Figure 2020-2030 MEA Non-Alcoholic Steatohepatitis Drug Market Size and CAGR; Table 2020-2030 MEA Non-Alcoholic Steatohepatitis Drug Market Size by Application; Table 2020-2025 MEA Non-Alcoholic Steatohepatitis Drug Key Players Revenue; Table 2020-2025 MEA Non-Alcoholic Steatohepatitis Drug Key Players Market Share; Table 2020-2030 MEA Non-Alcoholic Steatohepatitis Drug Market Size by Type; Table 2020-2030 Egypt Non-Alcoholic Steatohepatitis Drug Market Size; Table 2020-2030 Israel Non-Alcoholic Steatohepatitis Drug Market Size; Table 2020-2030 South Africa Non-Alcoholic Steatohepatitis Drug Market Size; Table 2020-2030 Gulf Cooperation Council Countries Non-Alcoholic Steatohepatitis Drug Market Size; Table 2020-2030 Turkey Non-Alcoholic Steatohepatitis Drug Market Size; Table 2020-2025 Global Non-Alcoholic Steatohepatitis Drug Market Size by Region; Table 2020-2025 Global Non-Alcoholic Steatohepatitis Drug Market Size Share by Region; Table 2020-2025 Global Non-Alcoholic Steatohepatitis Drug Market Size by Application; Table 2020-2025 Global Non-Alcoholic Steatohepatitis Drug Market Share by Application; Table 2020-2025 Global Non-Alcoholic Steatohepatitis Drug Key Vendors Revenue; Figure 2020-2025 Global Non-Alcoholic Steatohepatitis Drug Market Size and Growth Rate; Table 2020-2025 Global Non-Alcoholic Steatohepatitis Drug Key Vendors Market Share; Table 2020-2025 Global Non-Alcoholic Steatohepatitis Drug Market Size by Type; Table 2020-2025 Global Non-Alcoholic Steatohepatitis Drug Market Share by Type; Table 2025-2030 Global Non-Alcoholic Steatohepatitis Drug Market Size by Region; Table 2025-2030 Global Non-Alcoholic Steatohepatitis Drug Market Size Share by Region; Table 2025-2030 Global Non-Alcoholic Steatohepatitis Drug Market Size by Application; Table 2025-2030 Global Non-Alcoholic Steatohepatitis Drug Market Share by Application; Table 2025-2030 Global Non-Alcoholic Steatohepatitis Drug Key Vendors Revenue; Figure 2025-2030 Global Non-Alcoholic Steatohepatitis Drug Market Size and Growth Rate; Table 2025-2030 Global Non-Alcoholic Steatohepatitis Drug Key Vendors Market Share; Table 2025-2030 Global Non-Alcoholic Steatohepatitis Drug Market Size by Type; Table 2025-2030 Non-Alcoholic Steatohepatitis Drug Global Market Share by Type